Press "Enter" to skip to content

New Blood-thinning Drugs “Might Be Safer than Warfarin”

A research study conducted at the University of Nottingham (UoN) has discovered a more secure blood-thinning drug. The latest drug is far less likely to allow for bleeding.

The research study proclaims that about 17 Million times patients were prescribed for the blood thinners last year. The resent research in the BMJ studied almost 200,000 patients over 5 Years. The results of the research report proved that the newer blood-thinning drugs can be far safer than the regularly prescribed medicine, warfarin.

Until in recent times, thousands of patients with the risk of strokes and heart attacks were prescribed with warfarin. However, there is a possibility that it could be responsible for the bleeding in brain and stomach of an individual. So, the need for the patient’s closely monitoring occurred.

The recent research study is published in the British Medical Journal. It analyzed about 196,061 patients using warfarin or DOACs between 2011 and 2016. A study at UoN discovered that there is an alternative to drug warfarin. It is another type of blood-thinning drug that is less harmful. The drug is called as a direct oral anticoagulant (DOAC).

In the past 8 Years, there is an increase in the DOACs prescription by doctors. However, until now, very little has been known about their side effects. These drugs stop the blood from clotting. If the blood is not prevented from clotting, it can lead to a heart attack or stroke.

On a related note, Leonard Design Architects and UoN have announced a new partnership. The recent collaboration is aimed to achieve an improvement in the research and development in the architectural sector.

The recent initiative will let the students of UoN school of architecture work directly with local firms. This will offer an opportunity for these students to generate advanced industry-based research.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *